Campbell & Co Investment Adviser’s Amicus Therapeutics FOLD Stock Holding History

Campbell & Co Investment Adviser’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-656,111	Closed	-$3.76M	–	1195
2025 Q2	$3.76M	Buy	+656,111	New	+$4.23M	0.24%	83
2024 Q4	–	Sell	-176,253	Closed	-$1.88M	–	1151
2024 Q3	$1.88M	Buy	176,253 +163,721	+1,306%	+$1.78M	0.14%	201
2024 Q2	$124K	Sell	12,532 -5,968	-32%	-$61.3K	0.01%	991
2024 Q1	$218K	Sell	18,500 -151,931	-89%	-$1.94M	0.02%	999
2023 Q4	$2.42M	Buy	170,431 +159,419	+1,448%	+$1.81M	0.22%	90
2023 Q3	$134K	Buy	+11,012	New	+$142K	0.02%	884
2022 Q4	–	Sell	-14,939	Closed	-$156K	–	848
2022 Q3	$156K	Buy	+14,939	New	+$166K	0.04%	655
2021 Q2	–	Sell	-44,136	Closed	-$436K	–	581
2021 Q1	$436K	Buy	+44,136	New	+$683K	0.27%	123
2019 Q4	–	Sell	-44,106	Closed	-$354K	–	706
2019 Q3	$354K	Buy	+44,106	New	+$479K	0.13%	309

Other funds holding FOLD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Campbell & Co Investment Adviser's FOLD Position: Q3 2025 in Review

Campbell & Co Investment Adviser sold out of Amicus Therapeutics (FOLD) in Q3 2025, closing a stake of 656,111 shares — an estimated $3.76M sold.

Campbell & Co Investment Adviser first reported a position in FOLD in Q3 2019 and held it in 9 quarters. The position peaked at $3.76M in Q2 2025. 287 funds tracked by Wall St. Rank hold FOLD as of Q3 2025.

Campbell & Co Investment Adviser reported no remaining Amicus Therapeutics position as of Q3 2025 after selling out during the quarter.
Campbell & Co Investment Adviser sold 656,111 Amicus Therapeutics shares in Q3 2025, an estimated $3.76M.
Campbell & Co Investment Adviser first reported a position in Amicus Therapeutics in Q3 2019 and held it in 9 quarters.
Campbell & Co Investment Adviser's Amicus Therapeutics position peaked at $3.76M in Q2 2025.
287 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2025.

Based on Campbell & Co Investment Adviser's 13F filing for Q3 2025, filed 28 Oct 2025.